QQQ   309.16 (-2.90%)
AAPL   122.06 (-2.45%)
MSFT   227.56 (-2.70%)
FB   255.41 (-1.39%)
GOOGL   2,011.41 (-2.57%)
TSLA   653.20 (-4.84%)
AMZN   3,005.00 (-2.89%)
NVDA   512.19 (-4.49%)
BABA   236.27 (+0.79%)
CGC   33.24 (-5.70%)
GE   13.44 (+3.54%)
MU   89.11 (-2.17%)
NIO   41.53 (-4.07%)
AMD   80.86 (-3.89%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   520.70 (-4.95%)
PFE   34.39 (+2.63%)
QQQ   309.16 (-2.90%)
AAPL   122.06 (-2.45%)
MSFT   227.56 (-2.70%)
FB   255.41 (-1.39%)
GOOGL   2,011.41 (-2.57%)
TSLA   653.20 (-4.84%)
AMZN   3,005.00 (-2.89%)
NVDA   512.19 (-4.49%)
BABA   236.27 (+0.79%)
CGC   33.24 (-5.70%)
GE   13.44 (+3.54%)
MU   89.11 (-2.17%)
NIO   41.53 (-4.07%)
AMD   80.86 (-3.89%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   520.70 (-4.95%)
PFE   34.39 (+2.63%)
QQQ   309.16 (-2.90%)
AAPL   122.06 (-2.45%)
MSFT   227.56 (-2.70%)
FB   255.41 (-1.39%)
GOOGL   2,011.41 (-2.57%)
TSLA   653.20 (-4.84%)
AMZN   3,005.00 (-2.89%)
NVDA   512.19 (-4.49%)
BABA   236.27 (+0.79%)
CGC   33.24 (-5.70%)
GE   13.44 (+3.54%)
MU   89.11 (-2.17%)
NIO   41.53 (-4.07%)
AMD   80.86 (-3.89%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   520.70 (-4.95%)
PFE   34.39 (+2.63%)
QQQ   309.16 (-2.90%)
AAPL   122.06 (-2.45%)
MSFT   227.56 (-2.70%)
FB   255.41 (-1.39%)
GOOGL   2,011.41 (-2.57%)
TSLA   653.20 (-4.84%)
AMZN   3,005.00 (-2.89%)
NVDA   512.19 (-4.49%)
BABA   236.27 (+0.79%)
CGC   33.24 (-5.70%)
GE   13.44 (+3.54%)
MU   89.11 (-2.17%)
NIO   41.53 (-4.07%)
AMD   80.86 (-3.89%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   520.70 (-4.95%)
PFE   34.39 (+2.63%)
Log in

Nomura's rating of Marker Therapeutics, Inc. on 6/24/2020

unlock icon Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.